ropanicant
{{Short description|Neurological drug under development}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| drug_name = Ropanicant
| image =Ropanicant.svg
| width = 250px
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| dependency_liability =
| addiction_liability =
| routes_of_administration =
| class =
| ATC_prefix =
| ATC_suffix =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 2414674-70-5
| CAS_supplemental =
| PubChem = 146026959
| IUPHAR_ligand = 10700
| DrugBank = DB19134
| ChemSpiderID = 127383388
| UNII = S3VP91C4JO
| KEGG =
| ChEBI =
| ChEMBL = 4650579
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = SUVN-911
| IUPAC_name = (1R,3S,5R)-3-[(6-chloropyridin-3-yl)oxymethyl]-2-azabicyclo[3.1.0]hexane
| C=11 | H=13 | Cl=1 | N=2 | O=1
| SMILES =C1[C@H]2C[C@H]2N[C@@H]1COC3=CN=C(C=C3)Cl
| StdInChI =S/C11H13ClN2O/c12-11-2-1-9(5-13-11)15-6-8-3-7-4-10(7)14-8/h1-2,5,7-8,10,14H,3-4,6H2/t7-,8-,10+/m0/s1
| StdInChIKey = PYSCVJMLJRHJGJ-OYNCUSHFSA-N
}}
Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and other neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects. By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.
Clinical trials
The compound has completed Phase 1 and Phase 2 clinical trials for moderate to severe major depressive disorder.{{cite journal | vauthors = Nirogi R, Benade V, Goyal VK, Pandey SK, Mohammed AR, Shinde A, Dogiparti D, Ravula J, Jetta S, Palacharla VR | title = Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects | journal = Clinical Drug Investigation | volume = 42 | issue = 9 | pages = 747–762 | date = September 2022 | pmid = 35963959 | doi = 10.1007/s40261-022-01189-9 }}{{cite journal | vauthors = Nirogi R, Abraham R, Jayarajan P, Goura V, Kallepalli R, Medapati RB, Tadiparthi J, Goyal VK, Pandey SK, Subramanian R, Petlu S, Thentu JB, Palacharla VR, Gagginapally SR, Mohammed AR, Jasti V | title = Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization | journal = Psychopharmacology | volume = 239 | issue = 7 | pages = 2215–2232 | date = July 2022 | pmid = 35298691 | doi = 10.1007/s00213-022-06108-6 }} Preliminary studies have explored its potential for a faster onset of action compared to conventional antidepressants.{{cite journal | vauthors = Nirogi R, Mohammed AR, Shinde AK, Ravella SR, Bogaraju N, Subramanian R, Mekala VR, Palacharla RC, Muddana N, Thentu JB, Bhyrapuneni G, Abraham R, Jasti V | title = Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression | journal = Journal of Medicinal Chemistry | volume = 63 | issue = 6 | pages = 2833–2853 | date = March 2020 | pmid = 32026697 | doi = 10.1021/acs.jmedchem.9b00790 }} In addition to its investigation in depression, ongoing research is examining its possible use in treating neurodegenerative disorders such as Alzheimer’s disease.{{cite journal | vauthors = Kocienski P | title = Synthesis of SUVN-911. | journal = Synfacts | date = June 2020 | volume = 16 | number = 626 | page = 0626 | doi = 10.1055/s-0040-1707534 }}
See also
References
{{reflist}}
{{Stimulants}}
{{Analgesics}}
{{Nicotinic acetylcholine receptor modulators}}
Category:Cyclopentyl compounds
{{Pharma-stub}}